论文部分内容阅读
目的 :观察复合α干扰素 (CIFN)联合病毒唑治疗慢性丙型肝炎的临床效果及用药安全性 ,探讨临床抗慢性丙型肝炎病毒的方法。方法 :选择 6 8例慢性丙型肝炎患者并随机分成联合治疗组与对照组。联合治疗组 38例 ,给予CIFN 15 μg ,隔日皮下注射 ,加病毒唑 45 0mg ,tid口服 ,疗程为 6个月 ;对照组 30例 ,单用干扰素α 2b ,3MU ,隔日肌注 1次 ,疗程 6个月 ;两组停药后随访 6个月。观察两组治疗前后的临床症状、体征改善状况 ,生化应答率 ,病毒应答率和临床副作用。结果 :疗程结束时联合治疗组临床症状、体征的缓解率为 89 47% ,生化应答率为89 47% ,病毒应答率为 71 0 5 % ;对照组分别为 83 34%、83 34%、6 6 6 7% (均P >0 0 5 )。随访 6个月 ,联合治疗组的持续应答率为 47 37% ,而对照组为 16 6 7% (P <0 0 5 )。两组副作用均有发热、乏力、胃肠道症状、白细胞下降、肌肉酸痛等 (P >0 0 5 )。结论 :CIFN联合病毒唑治疗慢性丙型肝炎 ,可迅速缓解患者的症状体症 ,促进HCV RNA阴转 ,停药 6个月后的持续完全应答显著优于单用干扰素。临床应用安全。
Objective: To observe the clinical effect and medication safety of combination interferon-alpha (CIFN) and ribavirin in the treatment of chronic hepatitis C and to explore the clinical methods of anti - chronic hepatitis C virus. Methods: Sixty-eight patients with chronic hepatitis C were selected and randomly divided into combined treatment group and control group. In the combined treatment group, 38 cases were given CIFN 15 μg, subcutaneously every other day, plus ribavirin 45 0 mg and tid orally for 6 months. In the control group, 30 cases were treated with interferon α 2b and 3MU alone, Course of 6 months; two groups were followed up for 6 months after stopping. The clinical symptoms, signs and symptoms, biochemical response rate, virus response rate and clinical side effects were observed before and after treatment. Results: At the end of the course of treatment, the rates of clinical symptoms and signs were 89 47%, the rate of biochemical response was 89 47%, and the rate of virus response was 71 0 5%. The control group was 83 34% and 83 34%, respectively 6 6 7% (all P> 0 0 5). After a follow-up of 6 months, the sustained response rate was 47.37% in the combination group and 16.6% (P <0.05) in the control group. Both side effects were fever, fatigue, gastrointestinal symptoms, leukopenia, muscle soreness (P> 0.05). Conclusion: CIFN combined with ribavirin in the treatment of chronic hepatitis C can promptly relieve the symptoms of patients and promote the HCV RNA negative conversion. The sustained and complete response after 6 months withdrawal is significantly better than that of interferon alone. Clinical application of safety.